Page 50 - Read Online
P. 50
Editorial
Introduction to Volume 1 Issue 2 of Journal of Cancer Metastasis and
Treatment
Lucio Miele
Stanley Scott Cancer Center, Louisiana State Health Sciences Center and Louisiana Cancer Research Consortium, New Orleans, LA 70112, USA.
Correspondence to: Prof. Lucio Miele, Stanley Scott Cancer Center, Louisiana State Health Sciences Center and Louisiana Cancer Research
Consortium, New Orleans, LA 70112, USA. E-mail: lmiele@lsuhsc.edu
It is my privilege to introduce the second issue of the for the management of squamous non-small cell lung
Journal of Cancer Metastasis and Treatment. In keeping cancer (NSCLC); and the pharmacological properties
with the format we have chosen for our journal, this of Withania somnifera extract in a triple-negative breast
issue contains two reviews focusing on fi elds of great cancer model. miRNAs and other non-coding RNAs in
translational and clinical interest, fi ve original articles, biological fl uids promise to revolutionize the world of
and three case reports. The fi rst review discusses the biomarkers. However, there remain signifi cant technical
rapidly evolving fi eld of circulating tumor cells (CTC) issues surrounding the reproducible quantifi cation of
as cancer biomarkers. Since the introduction of the fi rst miRNAs for clinical purposes. The manuscript by
Food and Drug Administration approved CTC test to Shalaby et al. is an example of progress in this highly
assess the progression of metastatic breast, colorectal promising fi eld. The manuscript by Zeeneldin et al.
and prostate cancer, CTC have generated tremendous describes the experience of treating diffuse large B-cell
interest among clinicians seeking sensitive progression NHL in a geriatric setting where safety and effi cacy
biomarkers and basic scientists interested in isolating considerations have be balanced against each other and
and studying these cells. A number of new sorting, where monoclonal antibodies are not always available.
capture, and enumeration technologies are being The study by Chivukula et al. proposes the intriguing
evaluated. Competing technologies have emerged, such hypothesis that immunohistochemical detection of
as circulating tumor DNA. The review by Potdar and the transcription factor GATA3 and “pioneer” factor
Lotey summarizes the current experience with CTC as FOXA1 has prognostic value in breast cancer. The
diagnostic and prognostic biomarkers and the future of manuscript by Savini et al. describes the experience
this technology. The review by Alfonso et al. describes of this group treating squamous NSCLC, analyzing
recent progress in our understanding of urothelial variables associated with improved survival in their
cancer, a poorly understood malignancy that can be very patient population. The article by Ray et al. describes
diffi cult to treat, based on novel translational science. the effect of a promising natural product, an extract from
The original articles cover a variety of translational and well-known medicinal plant Withania somnifera, on the
clinical topics: the rapidly growing fi eld of extracellular production of cytokines associated with metastasis in
microRNA (miRNA) detection and quantifi cation, as a standard triple-negative breast cancer model. Finally,
applied to medulloblastoma; the management of diffuse the three case reports describe unusual presentations,
large B-cell non-Hodgkin lymphoma (NHL) in elderly including histologically different metastases from an
Egyptian patients; the prognostic value of GATA3 and unknown primary lesion, orbital metastasis from rectal
FOXA1 detection in breast cancer; current clinical criteria carcinoma and a mature spinal teratoma presenting in an
elderly patient.
Access this article online
I hope you enjoy reading this issue, and the ones that
Quick Response Code: will follow.
Website:
www.jcmtjournal.com
How to cite this article: Miele L, Introduction to Volume 1 Issue 2
of Journal of Cancer Metastasis and Treatment. J Cancer Metastasis
Treat 2015;1:43.
DOI:
10.4103/2394-4722.160150 Received: 11-06-2015; Accepted: 18-06-2015.
Source of Support: Nil, Confl ict of Interest: None declared.
Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 2 ¦ July 15, 2015 ¦ 43